Inotek Pharmaceuticals Corporation
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Inotek Pharmaceuticals Corporation
Private Company Edition: Scion’s first fund exceeded its initial $250m fundraising goal. Also, The Column Group’s incubator raised a $400m-plus fund and Seroba’s fourth fund reaches $134m, while Neurona raised a $120m financing and Cour closed a $105m series A round.
VC Playbook: Hubert Birner, managing partner for Montreal and Munich, is responsible for TVM Capital Life Science’s overall investment approach and global fund operations. At the November 2023 BIO-Europe conference, he sat down with In Vivo to discuss the VC’s strategy and expectations for the European life science sector in 2024.
Plus deals involving Abliva/Owl, Selecta/Cartesian, Novo Nordisk/Genevant, AbbVie/Aldeyra and more.
The US firm’s Syfovre for geographic atrophy due to age-related macular degeneration was linked with a handful of cases of occlusive retinal vasculitis, according to a letter published by a top retinal society, but most analysts believe there is a reasonable explanation.
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.